Dazolic is commonly used to address infections caused by specific types of protozoa and anaerobic bacteria that are generally associated with symptoms that interfere with daily functioning. The medication is applied across domains where additional symptomatic support is needed due to microbial presence.

The active compound is commonly used for managing symptoms associated with conditions such as trichomoniasis, giardiasis, amebiasis, and bacterial vaginosis in adults. This use is generally aligned with official guidance for its core therapeutic class. This medication is relevant across conditions presenting with acute episodes in the genitourinary and gastrointestinal tracts.

Providing Symptom Relief and Comfort

Its use is relevant for easing the overall symptom burden and may assist with managing symptoms related to inflammatory or irritative states. This generally includes contributing to the improved comfort associated with irritation, burning, and itching, and assisting with managing offensive odour and unusual discharge. Its application is relevant when short-term symptomatic assistance is needed during phases when symptoms become more noticeable.

Quick Fact: Relief for Infection-Related Discomfort

Eligibility Map: Who Can and Cannot Use Dazolic (Ornidazole) — Official Regulatory Information

The regulatory eligibility profile for Dazolic is strictly defined by government health authorities, establishing clear restrictions and prohibitions for certain populations.

Eligibility Scope	Status as per Official Labeling
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Ornidazole or any other nitroimidazole derivative. Patients with known organic central nervous system (CNS) diseases [1.1, 1.3]. Women in the First Trimester of Pregnancy [1.3].
Age-Related Eligibility	Adults are the standard approved population. Pediatric use is often not recommended or not established below specific age or weight limits [1.3]. Geriatric use typically requires caution, though dose adjustments are not always mandated [1.1].
Condition-Specific Eligibility	Severe Hepatic Impairment requires caution, and a dose interval adjustment may be necessary due to prolonged elimination [2.5]. Severe Renal Impairment typically does not require a dose adjustment, but use is conditional for patients undergoing hemodialysis [1.5].
Reproductive Status	Pregnancy: Contraindicated in the first trimester [1.3]. Lactation: Not recommended; official guidance suggests interrupting breastfeeding during treatment [1.1, 1.5].

These formal eligibility statements ensure that the medicine is only used within the regulatory constraints set forth by authorities like the EMA and FDA.

Interactions with other medicines and products

This section summarizes the officially documented interactions for Dazolic (ornidazole), derived from regulatory information.

Pharmacokinetic Interactions (Drug Exposure)

Interactions that alter the concentration of ornidazole in the bloodstream are primarily related to liver enzyme metabolism. Co-administration with certain drugs can either increase or decrease ornidazole's exposure:

• Increased Ornidazole Exposure: Concurrent use of cimetidine may prolong the half-life and decrease the plasma clearance of ornidazole.
• Decreased Ornidazole Exposure: Co-administration with enzyme-inducing agents such as phenytoin or phenobarbital may reduce the half-life of ornidazole.

Pharmacodynamic Interactions (Effect Modification)

Ornidazole can enhance the effect of specific co-administered drugs:

• Oral Anticoagulants: Ornidazole may potentiate the anticoagulant effect of coumarin-type derivatives, such as warfarin. Close monitoring of international normalized ratio (INR) may be required.
• Muscle Relaxants: Ornidazole prolongs the muscle-relaxant effect of non-depolarizing agents, such as vecuronium bromide.

Substance and Timing Restrictions

• Alcohol: Strict avoidance of alcohol is required during treatment and for a minimum of three days after discontinuing Dazolic.
• 5-Fluorouracil: Ornidazole may reduce the clearance of 5-fluorouracil, potentially leading to increased toxicity of the chemotherapy agent.

How Dazolic Works: Mechanism of Action

The mechanism of Dazolic (Ornidazole) is one of highly selective destruction, triggered by specific internal conditions found only within susceptible pathogens.

---

Selective Bioactivation and Targeting of Anaerobic Metabolism

Ornidazole is an inactive prodrug that undergoes selective bioactivation once it enters the microbial cell. The drug's nitro group ( NO2) is reduced by specialized microbial nitroreductase enzymes and low-potential electrons, a process confined to the anaerobic environment of the pathogen. This initial interaction is critical as it converts the drug into highly cytotoxic free radicals and reactive intermediates. This selective activation process is chemically confined to the microbial cell.

Irreversible DNA Damage Leading to Cidal Effect

Once activated, these cytotoxic species rapidly cause irreversible damage by chemically fragmenting the microbe's DNA. This physical disruption immediately blocks essential nucleic acid functions, including replication and transcription. This cidal action—the active destruction of the microbial cell—ensures the systemic elimination of the susceptible pathogen, providing the core physiological consequence of microbial destruction.

Mechanistic Constraints on Oxygen Presence

This mechanism is inherently constrained by the environment. The toxic radicals necessary for DNA damage are easily neutralized (quenched) by the presence of oxygen, limiting the drug's activity in highly oxygenated tissues. Furthermore, the reliance on microbial nitroreductase activity means that microbes that develop reduced enzyme function results in reduced bioactivation.

Ornidazole is officially administered through two main routes: orally as a film-coated tablet, typically 500 mg in strength, or intravenously (IV) as a sterile solution for infusion. The choice between the oral and IV routes is determined by the specific clinical context, often based on the infection’s severity or the need for surgical prophylaxis.

The administration pattern for oral tablets is strictly post-prandial, meaning they must be taken after meals. Dosing frequency is highly regimen-specific; some official courses mandate a single high dose (1.5 g), while others require divided doses, often 500 mg taken twice daily (every 12 hours). The overall treatment duration is generally short, defined by the specific regimen, ranging from short courses of 1 to 3 days up to 10 days for more persistent conditions. For prophylaxis before surgery, a 1 g IV dose or a 1.5 g oral dose is administered shortly before the procedure.

Labeled instructions detail key dose adjustments for specific patient populations. For children under 35 kg, the dose is calculated based on body weight (e.g., 25 mg/kg/day or 40 mg/kg/day). In cases of severe hepatic impairment, the standard dosing interval must be doubled to prevent drug accumulation. Additionally, patients receiving hemodialysis require a supplemental dose (250 mg to 500 mg) after each session. For intravenous use, the solution must be diluted to 5 mg/mL or less and infused slowly over 15 to 30 minutes.

Research Evidence / Overview of Studies for Dazolic (Ornidazole)

This overview summarizes the formal research base for the active substance Ornidazole, describing the types of studies conducted and the context of the evidence, without providing medical advice or treatment recommendations.

---

Research Landscape for Protozoal and Parasitic Infections

Studies have examined the use of Ornidazole for conditions characterized by functional imbalance caused by protozoa, including Giardiasis, Trichomoniasis, and Amebiasis. The research landscape for these uses includes both Clinical Trials and Systematic Reviews that were foundational in the development of the drug class. Studies monitored outcomes such as the parasitological cure rate (clearance of the organism) and the resolution of episodic or acute symptoms.

For Giardiasis and Trichomoniasis, research describes patterns of parasite clearance in the observed populations after short treatment periods. However, for Amebiasis, a significant portion of the evidence is older and often suffers from limited sample sizes or methodological weaknesses, meaning certainty remains low in some settings.

Research Landscape for Bacterial Vaginosis (BV) and Anaerobic Infections

Ornidazole was studied for its application in Bacterial Vaginosis (BV) and in the prophylaxis of surgical site infections (SSI), conditions associated with acute or disruptive episodes linked to anaerobic bacteria. For BV, researchers conducted Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. Studies monitored the Clinical Cure Rate, which measures the pattern of physical discomfort and specific diagnostic markers.

Research protocols monitored regimens involving Ornidazole as part of a combination used in surgical settings, particularly elective colorectal surgery, monitoring the incidence of SSI within a defined post-operative interval. Studies monitored patterns in the frequency of post-operative infections, and research describes the observed difference in rates between the group receiving the regimen and the comparison group in some studies.

---

Areas Where Research is Still Developing

Evidence highlights what is known and what is still uncertain. Evidence quality varies across studies, particularly for older indications like Amebiasis. Comparative evidence is lacking in some areas for direct, head-to-head evaluation against every newer treatment alternative. Furthermore, many studies primarily focus on achieving acute clearance, and data are still emerging regarding long-term recurrence patterns and the stability of the response.

Key Studies & References

1. Comparative Effectiveness of Treatments for Bacterial Vaginosis: A Network Meta-Analysis
2. Summary of a systematic review on surgical antibiotic prophylaxis prolongation (WHO Surgical Site infection Prevention Guidelines Web Appendix 25)
3. Efficacy of ornidazole for pericoronitis: a meta-analysis and systematic review

Common questions about Dazolic (FAQ)

Q: What specific types of infections is Dazolic typically prescribed for?

A: Official product information states that Dazolic is used to treat infections caused by susceptible bacteria and parasites. These conditions often include amoebiasis, giardiasis, and trichomoniasis. It is also used for bacterial vaginosis and is indicated as a preventative measure for certain post-operative infections.

Q: What is the usual duration of a course of Dazolic treatment?

A: According to regulatory documents, the duration of treatment is specific to the condition being treated and the dosing regimen chosen. Courses can vary significantly, ranging from very short treatments of 1 to 10 days for more persistent conditions. The precise length of treatment will be determined based on a professional medical evaluation.

Q: Is it typical for Dazolic to cause stomach discomfort or changes in appetite?

A: Yes, official safety information indicates that common side effects can involve the gastrointestinal system. These may include digestive disorders, abdominal pain, and sometimes a temporary loss of appetite (anorexia).

Q: What are the signs of a serious allergic reaction to Dazolic that require urgent medical attention?

A: Serious allergic reactions, such as anaphylaxis and angioedema (swelling beneath the skin), have been documented. Signs can include severe or widespread skin reactions like hives, or significant swelling of the face, tongue, or throat. A medical professional should be consulted immediately if these signs are observed.

Q: How long after finishing the Dazolic course is it safe to consume alcohol again?

A: Official warnings state that alcohol must be avoided during treatment and for a minimum of 3 days (72 hours) after the last dose to prevent a potentially severe adverse reaction. This requirement is in place due to the risk of a disulfiram-like reaction.

Q: Does Dazolic pose any specific risks for older adult patients?

A: Official warnings suggest that the use of Dazolic in the elderly population generally requires caution. Although specific dose adjustments are not always needed for Dazolic itself, monitoring kidney function may be necessary if a combination treatment is being used. Any decision regarding use in the elderly should be based on a comprehensive medical assessment.

Q: What should be done if a dose of Dazolic is accidentally missed?

A: Official regulatory guidance addresses the procedure for a missed dose, which typically involves taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. It is usually advised not to take a double dose to compensate for the forgotten one.

Q: What are the symptoms of a Dazolic overdose, and what should someone do?

A: Overdose can increase the risks of severe central nervous system effects. Symptoms may include a severe lack of coordination (ataxia), slurred speech (dysarthria), and, in rare cases, seizures. In the event of a suspected overdose, immediate contact with emergency medical services is necessary.

Q: Can Dazolic increase sensitivity to light or cause blurred vision?

A: Regulatory documents indicate that visual side effects, such as blurred vision or double vision (diplopia), have been reported with this drug class. These effects are primarily associated with high-dose or long-term use of nitroimidazole drugs.

Q: Why do some people report feeling shaky or having poor coordination while on Dazolic?

A: This medication can have effects on the central nervous system. Adverse neurological effects reported include dizziness, loss of coordination (ataxia), and, rarely, involuntary limb tremors. The occurrence of these effects should be discussed with a healthcare provider.

Q: Does Dazolic cause skin reactions like rashes or itching?

A: Skin rash and itching are listed in official safety documents as uncommon side effects. In very rare cases, more severe skin reactions, such as erythema multiforme, have been reported.

Q: What steps can be taken to lessen the metallic taste side effect from Dazolic?

A: The unpleasant metallic taste is a common side effect of Dazolic. Official product information suggests that consuming sugarless candies or lozenges may help manage or minimize the metallic taste while the medicine is being taken.

Q: What information is available regarding the safety of Dazolic for people undergoing haemodialysis?

A: Official regulatory data confirms that the active substance, Ornidazole, is removed from the body during haemodialysis. Because of this, patients undergoing dialysis typically require a supplemental dose of the medicine to be administered after each session to maintain effective levels in the body.

Q: Does Dazolic's effectiveness differ depending on the specific strain of bacteria or protozoa causing the infection?

A: Yes, the effectiveness of Dazolic is highly selective, dependent on the susceptibility of the organism causing the infection. Regulatory evidence confirms the drug is effective only against susceptible strains of bacteria and protozoa.

Q: Does the brand name Dazolic have generic equivalents, and is the active ingredient the same?

A: The active ingredient in Dazolic is Ornidazole. Since Ornidazole is a well-defined chemical substance, it is available as a generic drug and is marketed internationally under various other brand names.

Q: Can Dazolic be used to treat infections in the brain or nervous system?

A: Ornidazole is reported to cross the blood-brain barrier and is indicated for certain infections of the brain. However, its use is typically contraindicated in patients who have pre-existing central nervous system disorders.

Q: Does taking Dazolic for a long period increase the risk of certain side effects?

A: Regulatory safety information indicates that the risk of serious side effects is associated with taking Dazolic in high doses or for a prolonged duration. Specifically, there is an elevated risk of nerve damage (neuropathy) or effects on the brain (encephalopathy).

Q: Can Dazolic affect sleep, causing sleeplessness or making me feel unusually tired?

A: Yes, official product information lists both sleeplessness (insomnia) and unusual tiredness or weakness as reported side effects. These are linked to the drug's activity on the central nervous system.

Q: Can Dazolic be safely used by women who are pregnant or planning to conceive?

A: The safety of Dazolic during pregnancy has not been definitively established, and it is contraindicated during the first trimester. Any use beyond the first trimester requires a careful evaluation by a medical professional to weigh the potential benefits against the risks involved.

Q: Can children or adolescents use Dazolic, and what precautions are necessary?

A: Yes, Dazolic can be used in children, but the dose must be precisely calculated based on the child's body weight, such as 40 mg per kilogram. Due to the need for precise dosing, the use of this medicine in children requires strict monitoring by a healthcare provider.

Q: Why is it crucial to finish the entire prescribed course of Dazolic even if symptoms improve early?

A: Regulatory guidance stresses the importance of completing the full prescribed course. This practice helps ensure the complete elimination of the infectious organisms, which prevents the infection from coming back and minimizes the potential for the organisms to develop drug resistance.

Q: Is it possible for Dazolic to cause nerve-related side effects, such as numbness or tingling (peripheral neuropathy)?

A: Yes, the official label includes warnings about the risk of nerve damage (peripheral neuropathy). This can manifest as numbness, tingling, or pain in the hands or feet, and the risk increases with prolonged treatment.

Q: Is there any research or evidence to suggest Dazolic can cause seizures or convulsions in susceptible individuals?

A: Official safety documents list seizures as a serious neurological side effect. Due to this risk, the medicine is generally contraindicated for patients with pre-existing epilepsy or other convulsion disorders.

Q: Can Dazolic be used in people with pre-existing nervous system disorders like Multiple Sclerosis?

A: Official warnings indicate that Dazolic should be used only with extreme caution in patients with pre-existing nervous system disorders, including Multiple Sclerosis. This is due to the potential for adverse effects on the central nervous system which could exacerbate the condition.

Q: Can Dazolic be taken with or without food, or does it depend on the type of infection?

A: Official guidance for the oral tablets indicates that Dazolic should be administered with or immediately following food (post-prandially). Taking the tablets with food may help to reduce the likelihood of experiencing stomach discomfort or irritation.

Q: Is it considered normal to experience joint or muscle pain while taking Dazolic?

A: Official safety listings indicate that both muscle pain (myalgia) and joint pain (arthralgia) are reported side effects, though they are considered rare. The occurrence of such symptoms should be discussed with a healthcare professional.

How to Store and Dispose of Dazolic?

The official storage and disposal guidelines for Dazolic (Ornidazole) are strictly defined in regulatory documents to maintain product quality and safety.

---

Storage Requirements

Dazolic tablets must be stored at a temperature not exceeding 30 °C and kept in a cool dry place. The medicine must be kept in its original blister pack and protected from environments with excessive heat and dampness, such as a bathroom or near a sink. It is a mandatory requirement to store Dazolic out of the sight and reach of children.

---

Stability and Disposal

The product must not be used after the expiry date printed on the packaging. Any unused, expired, or waste material must be disposed of in accordance with local requirements and regulations. Patients should consult a pharmacist for guidance on proper disposal.